Skip to content
HeyJared

Merle M. DeLancey Jr

Reporter

Indexed articles, last 90 days
3
Latest publication
Sep 29, 2026
Outlet visibility, for natlawreview.com
Top 1M sites
Earliest in this view
Aug 11, 2026

Latest articles

  1. Article · Sep 29, 2026 · Merle M. DeLancey Jr.

    Trump Administration Restricts Canadian Goods in Federal Procurement (opens the original)

    Excerpt · English

    Read excerpt

    President Trump signed a presidential memorandum titled “Restoring Reciprocity in Government Procurement” on September 16, 2026. The memorandum directs federal officials to take steps to restrict certain Canadian-origin products from the federal civilian procurement system. The action responds to Canada’s “Buy Canadian” policies, which prioritize Canadian suppliers and goods in government procurement. The memorandum aligns with the administration’s broader procurement and trade reforms. Earlier

  2. Article · Sep 11, 2026 · Merle M. DeLancey Jr.

    VA OIG Releases Report on the Federal Supply Schedule Program (opens the original)

    Excerpt · English

    Read excerpt

    On September 9, the Department of Veterans Affairs (“VA”) Office of Inspector General (“OIG”) released its findings based on a review of the VA Federal Supply Schedule (“FSS”) Program. See, VA Federal Supply Schedule Contracts. The VA and other government agencies annually purchase approximately $25 billion in medical equipment, pharmaceuticals, and services through the VA FSS Program. The OIG’s findings are based on information identified during its VA FSS contract audits. The report sets forth

  3. Article · Aug 11, 2026 · Merle M. DeLancey Jr.

    Court of Federal Claims Reaffirms Agency Discretion in TAA Country-of-Origin Determinations for Pharmaceuticals (opens the original)

    Excerpt · English

    Read excerpt

    On July 28, 2026, the U.S. Court of Federal Claims issued its decision in AvKare, LLC v. United States[1], upholding the Department of Veterans Affairs’ (“VA”) national contract award for Hydroxychloroquine tablets. The opinion is an important reminder of the discretion contracting officers have to evaluate pharmaceuticals for Trade Agreements Act (“TAA”) compliance and reaffirms that the country where a drug’s active pharmaceutical ingredient (“API”) is synthesized can be its country of origin

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

Top 1M sites

For natlawreview.com, the outlet · Measured Aug 1, 2026

Website popularity band, not a count of readers or article views.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Merle M. DeLancey Jr